يعرض 1 - 10 نتائج من 23 نتيجة بحث عن '"Lidia Mongay"', وقت الاستعلام: 1.37s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

    المؤلفون: Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann

    المصدر: CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1666-1686 (2023)

    مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2163-8306Test

    الوصول الحر: https://doaj.org/article/9de2185aad9e42999937070a78e87dc0Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

    المؤلفون: Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Timothy P. Hughes

    المصدر: Haematologica, Vol 97, Iss 6 (2012)

    مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

    وصف الملف: electronic resource

    العلاقة: https://haematologica.org/article/view/6331Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

    الوصول الحر: https://doaj.org/article/c9ad3ceda3a94149b72205c47d2cb76dTest

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  3. 3
    Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

    المؤلفون: Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

    المصدر: Blood. 140:6470-6473

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8381c7574c90effb8ae1911cddd54674Test
    https://doi.org/10.1182/blood-2022-167368Test


    أضف إلى المفضلة
  4. 4
    Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

    المؤلفون: Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Matthew J. Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Peter N. Morcos

    المصدر: Blood. 140:3629-3631

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::460077556e84544f792a462072cccb8dTest
    https://doi.org/10.1182/blood-2022-162819Test


    أضف إلى المفضلة
  5. 5
    Abstract CT082: Next-generation sequencing (NGS) and cytokine assessment from a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL) - associations with survival endpoints

    المؤلفون: Shalini Chaturvedi, Anke Weispfenning, David Bauer, Rong Du, Tine Descamps, Sara Bellinvia, Teresa Lunt, Lidia Mongay Soler, Barrett H. Childs, Pier Luigi Zinzani

    المصدر: Cancer Research. 83:CT082-CT082

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::94c81bd32feb3b9df15fd840f4498f13Test
    https://doi.org/10.1158/1538-7445.am2023-ct082Test


    أضف إلى المفضلة
  6. 6
    Abstract A32: Copanlisib plus rituximab vs placebo plus rituximab in patients with follicular lymphoma: 1-year follow-up of the Phase III, randomized CHRONOS-3 trial

    المؤلفون: Marcelo Capra, Fangfang Lv, Wei Li, Tongyu Lin, Eduardo Yañez, Jifeng Feng, Aryan Hamed, Xiaoling Li, Toshiki Uchida, Ming-Chung Wang, Koji Izutsu, Antonio Salar, Katya Sapunarova, Guray Saydam, Jan Zaucha, Lidia Mongay Soler, Shalini Chaturvedi, Anjun Cao, Barrett H Childs, Pier Luigi Zinzani, Matthew J Matasar

    المصدر: Blood Cancer Discovery. 3:A32-A32

    مصطلحات موضوعية: General Medicine

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1ea8ee0ba173a4ff09ca8cd98cfd6c9eTest
    https://doi.org/10.1158/2643-3249.lymphoma22-a32Test


    أضف إلى المفضلة
  7. 7
    Abstract A25: Copanlisib population pharmacokinetics (popPK) and exposure-response (ER) in relapsed indolent non-Hodgkin lymphoma (iNHL): Analysis from the 1-year follow-up of the phase III, randomized CHRONOS-3 trial

    المؤلفون: Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Patricia DeLora, Matthew J Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H Childs, Peter N Morcos

    المصدر: Blood Cancer Discovery. 3:A25-A25

    مصطلحات موضوعية: General Medicine

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b83177671f206cd279a2010b39bcf6c0Test
    https://doi.org/10.1158/2643-3249.lymphoma22-a25Test


    أضف إلى المفضلة
  8. 8
    Abstract LB523: Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL)

    المؤلفون: Shalini Chaturvedi, Anke Schulz, Lidia Mongay Soler, Barrett H. Childs, Matthew Matasar, Pier Luigi Zinzani

    المصدر: Cancer Research. 82:LB523-LB523

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2cc933cf61f31719b7834ac524b00e9cTest
    https://doi.org/10.1158/1538-7445.am2022-lb523Test


    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3) : a double-blind, randomised, placebo-controlled, phase 3 trial

    المؤلفون: Matasar, Matthew J., Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yanez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Baker, Ross, Bondarenko, Igor, Zhang, Qingyuan, Feng, Jifeng, Geissler, Klaus, Lazaroiu, Mihaela, Saydam, Guray, Szomor, Árpád, Bouabdallah, Krimo, Galiulin, Rinat, Uchida, Toshiki, Soler, Lidia Mongay, Cao, Anjun, Hiemeyer, Florian, Mehra, Aruna, Childs, Barrett H., Shi, Yuankai, Zinzani, Pier Luigi

    العلاقة: The Lancet Oncology, T. 22, nr 5, s. 678-689; https://ruj.uj.edu.pl/xmlui/handle/item/289981Test

    الإتاحة: https://doi.org/10.1016/S1470-2045Test(21)00145-5
    https://ruj.uj.edu.pl/xmlui/handle/item/289981Test

    View record in BASE

    أضف إلى المفضلة
  10. 10
    Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

    المؤلفون: Aryan Hamed, Güray Saydam, Muhit Ozcan, Aruna Mehra, Klaus Geissler, Florian Hiemeyer, Yuankai Shi, Toshiki Uchida, Árpád Szomor, Rinat Galiulin, Lidia Mongay Soler, Fangfang Lv, Eduardo Yanez, Igor Bondarenko, Katya Sapunarova, Matthew J. Matasar, Marcelo Capra, Anjun Cao, Jifeng Feng, Pier Luigi Zinzani, Mihaela Lazaroiu, Krimo Bouabdallah, Jie Jin, Wei Li, Qingyuan Zhang, Wojciech Jurczak, T. Lin, Barrett H. Childs, Ming-Chung Wang, Ross Baker

    المساهمون: Matasar M.J., Capra M., Ozcan M., Lv F., Li W., Yanez E., Sapunarova K., Lin T., Jin J., Jurczak W., Hamed A., Wang M.-C., Baker R., Bondarenko I., Zhang Q., Feng J., Geissler K., Lazaroiu M., Saydam G., Szomor A., Bouabdallah K., Galiulin R., Uchida T., Soler L.M., Cao A., Hiemeyer F., Mehra A., Childs B.H., Shi Y., Zinzani P.L.

    المصدر: The Lancet. Oncology. 22(5)

    مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Follicular Lymphoma, Phases of clinical research, Placebo, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, immune system diseases, Recurrence, Internal medicine, hemic and lymphatic diseases, Phosphoinositide-3 Kinase Inhibitor, Antineoplastic Combined Chemotherapy Protocols, Indolent Non-Hodgkin Lymphoma, Medicine, Humans, Monoclonal-Antibody Therapy, Copanlisib, Aged, Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocol, business.industry, Lymphoma, Non-Hodgkin, Response Assessment, Quinazoline, Middle Aged, medicine.disease, Lymphoma, Clinical trial, 030104 developmental biology, Pyrimidines, Oncology, chemistry, Pyrimidine, 030220 oncology & carcinogenesis, Quinazolines, Rituximab, Female, business, medicine.drug, Human

    وصف الملف: STAMPA

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82ee2a7756199e31b9767599176fede8Test
    https://pubmed.ncbi.nlm.nih.gov/34087150Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث